New Experimental Compound Burns Fat Without Muscle Loss in Obesity Study

• TOFA promotes fat loss and improves glucose control by increasing cellular energy expenditure rather than suppressing caloric intake.
• Preclinical experiments in mice demonstrated that the compound preserves lean muscle mass and avoids the triglyceride elevations typical of other ACC inhibitors.
• Combining TOFA with existing GLP-1 drugs produced additive improvements in body weight and metabolic markers.

Over the past five years, medications like semaglutide and tirzepatide have fundamentally altered the treatment of metabolic disorders, achieving significant reductions in body weight and blood glucose. Sold under brand names including Ozempic, Wegovy, Mounjaro, and Zepbound, these therapies rely heavily on appetite suppression. However, that mechanism introduces distinct clinical challenges, including gastrointestinal side effects, nutritional deficits, and muscle loss, which can lead to frailty. Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and senior author of the study, noted that body weight regulation depends on balancing caloric intake against energy expenditure. Because existing therapies focus almost entirely on intake, the research team investigated ways to stimulate output instead.

Originally discovered in the 1970s, TOFA belongs to a class of pharmacological agents known as ACC inhibitors, which block the production of lipids in the body. Although several ACC inhibitors advanced to mid-stage clinical testing, none achieved regulatory approval for metabolic disease because they frequently triggered elevations in triglycerides, posing a risk to heart health. To overcome this hurdle, the UC Berkeley team investigated TOFA’s specific molecular footprint. According to the study, TOFA operates through a dual mechanism. Beyond acting as an ACC inhibitor to block lipid production, the compound simultaneously activates PPARα and PPARδ. These cellular receptors trigger genes responsible for fat uptake and burning it for energy.

In murine models, this dual action caused cells to elevate energy expenditure by up to 18 percent without altering basal body temperature or physical activity levels. Furthermore, the activation of lipid-burning pathways prevented the triglyceride elevations associated with other ACC inhibitors. Justin Y. Lee, a postdoctoral student at UCSF, who conducted the work as a Ph.D. student at Berkeley and first author of the study, explained that TOFA engages a coordinated metabolic response that manages excess lipids and glucose simultaneously. When investigators tested a pharmacological split approach—administering two separate compounds to block lipid synthesis and boost energy expenditure independently—the combination failed to match the metabolic efficacy achieved by TOFA alone.

Investigators also explored combinatorial treatment regimens, pairing TOFA with established GLP-1 drugs. In experimental models, administering TOFA alongside semaglutide or tirzepatide yielded superior outcomes in glucose control, insulin levels, triglyceride reduction, and overall weight management compared to either treatment alone. Näär characterized the relationship as complementary rather than as a replacement, suggesting that targeting both levers of energy balance could optimize results for patients with severe metabolic dysfunction.

As this experimental compound advances past preclinical milestones toward potential clinical translation, researchers must determine whether the metabolic profile observed in murine models translates safely to human physiology.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*